Info@ThinkPinkRocks.com

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

More:
Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Share

Leave a Reply

Solve : *
23 + 25 =